Search our Database of Scientific Publications and Authors

I’m looking for a

    577 results match your criteria Cardiovascular Therapeutics[Journal]

    1 OF 12

    Vascular dysfunction elicited by a crosstalk between periaortic adipose tissue and the vascular wall is reversed by pioglitazone.
    Cardiovasc Ther 2018 Feb 21. Epub 2018 Feb 21.
    Vascular Biology Lab, Institute of Experimental Medicine and Biology of Cuyo (IMBECU) CONICET and School of Medical Sciences, National University of Cuyo, Mendoza, Argentina.
    Aim: Perivascular adipose tissue (PVAT) is in intimate contact with the vessel wall and extravascular PVAT-derived inflammatory mediators may adversely influence atherosclerotic plaque formation and stability through outside-to-inside signalling. We sought to investigate the role of PVAT on the atheroma development in an experimental animal model of Metabolic Syndrome (MS) associated with oxidative stress and low-grade inflammatory state. We also studied the effect of Pioglitazone an insulin sensitizer, on the aortic wall and its surrounding PVAT, considering a bi-directional communication between both layers. Read More

    Head-to-head comparison of the heart rate variability between the bisoprolol transdermal patch and bisoprolol fumarate tablet.
    Cardiovasc Ther 2018 Feb 21. Epub 2018 Feb 21.
    Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
    Aim: The bisoprolol transdermal patch is a newly developed β-blocker designed to deliver its pharmaceutical ingredient through the skin surface. We aimed to compare the bisoprolol transdermal patch and bisoprolol fumarate tablet using the heart rate variability (HRV).

    Method: Eligible hypertensive patients received a 2-week administration with a 2. Read More

    Change in ALT levels after administration of HMG-CoA reductase inhibitors to subjects with pretreatment levels three times the upper normal limit in clinical practice.
    Cardiovasc Ther 2018 Feb 21. Epub 2018 Feb 21.
    Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
    Aim: Prescription of statins to patients with chronic liver disease whose alanine transaminase (ALT) is over three times the upper normal limit (UNL) is not recommended. In this study, we attempted to evaluate patients with baseline ALT levels > 3 × UNL who were prescribed statins without ethical problems, using electronic medical records.

    Methods: We enrolled subjects with ALT levels > 3 × UNL. Read More

    Effects of ivabradine on endothelial function, aortic properties and ventricular-arterial coupling in chronic systolic heart failure patients.
    Cardiovasc Ther 2018 Feb 20. Epub 2018 Feb 20.
    Cardiology Unit, University and ASST Spedali Civili, Brescia, Italy.
    Aim: Heart rate (HR) is an important prognostic factor in patients affected by chronic heart failure (CHF); ivabradine has been demonstrated to significantly reduce nonfatal myocardial infarction and hospitalization rate for acute heart failure and to improve left ventricular (LV) reverse remodelling, quality of life, exercise capacity and arterial elastance (Ea) in these patients. We aimed at evaluating the short-term effects of ivabradine on ventricular-arterial coupling (VAC), aortic stiffness and endothelial function in stable patients with CHF.

    Methods: we evaluated 30 consecutive CHF patients (LVEF≤ 35%, NYHA class II) with sinus rhythm and HR ≥ 70 bpm on optimized pharmacological therapy. Read More

    Doxycycline attenuates chronic intermittent hypoxia-induced atrial fibrosis in rats.
    Cardiovasc Ther 2018 Jan 29. Epub 2018 Jan 29.
    Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, 300211, P.R. China.
    Introduction: Atrial structural remodeling in the form of fibrosis contributes to the arrhythmic substrate in atrial fibrillation (AF). The aim of this study was to investigate the effects of doxycycline on chronic intermittent hypoxia (CIH)-induced atrial fibrosis and the pathophysiological mechanisms underlying such changes.

    Methods: A total of 30 Sprague-Dawley rats were randomized into three groups: Control group, CIH group, CIH with doxycycline treatment (CIH-D) group. Read More

    Inhibition of BRD4 attenuates cardiomyocyte apoptosis via NF-κB pathway in a rat model of myocardial infarction.
    Cardiovasc Ther 2018 Jan 20. Epub 2018 Jan 20.
    Department of Physiology and Pathophysiology, School of Basic Medical Science, Tianjin Medical University, Heping, Tianjin, China.
    Background: Myocardial infarction (MI) remains the most common cause of heart failure (HF) worldwide. For almost 50 years, HF has been recognized as a determinant of adverse prognosis after MI, but efforts to promote myocardial repair have failed to be translated into clinical therapies.

    Aims: In this study, we investigated the effects of BRD4 on cardiac function and the underlying mechanism. Read More

    A propensity score-matched comparison of biodegradable polymer vs second-generation durable polymer drug-eluting stents in a real-world population.
    Cardiovasc Ther 2018 Jan 8. Epub 2018 Jan 8.
    Department of Cardiology, National University Heart Centre, Singapore City, Singapore.
    Aims: The safety and efficacy of BP-DES compared to second-generation DP-DES remain unclear in the real-world setting. We compared the clinical outcomes of biodegradable polymer drug-eluting stents (BP-DES) with second-generation durable polymer drug-eluting stents (DP-DES) in an all-comer percutaneous coronary intervention (PCI) registry.

    Methods/results: The study included a cohort of 1065 patients treated with either BP-DES or DP-DES from January 2009 through October 2015. Read More

    Overexpression of miR-22 attenuates oxidative stress injury in diabetic cardiomyopathy via Sirt 1.
    Cardiovasc Ther 2017 Dec 29. Epub 2017 Dec 29.
    Key Laboratory of Biochemistry, Wuhan People's Hospital, Wuhan, China.
    Background/aims: Oxidative stress injury is believed to be important in diabetic cardiomyopathy. Recent evidence indicates that miR-22 plays an important role in various cardiovascular diseases, but the protective role of miR-22 in diabetic cardiomyopathy remains undetermined.

    Methods: Diabetes was induced in male C57BL/6 mice by intraperitoneal injection with streptozotocin combined with a high-fat diet, and miR-22 was overexpressed following transfection with adeno-associated virus. Read More

    Exenatide exhibits anti-inflammatory properties and modulates endothelial response to tumor necrosis factor α-mediated activation.
    Cardiovasc Ther 2017 Dec 28. Epub 2017 Dec 28.
    Department of Biochemistry, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
    Introduction: Cardiovascular disease is the main cause of mortality and morbidity in the industrialized world. Incretin-mimetic compounds such as exenatide are currently used in the treatment of type 2 diabetes.

    Aims: We investigated the effects of incretin drugs on apoptosis, adhesion molecule expression, and concentration of extracellular matrix (ECM) metalloproteinases under inflammatory conditions within the context of atherosclerotic plaque formation of both human coronary artery endothelial cells (hCAECs) and human aortic endothelial cells (hAoECs). Read More

    Nicorandil for the prevention of contrast-induced nephropathy: A meta-analysis of randomized controlled trials.
    Cardiovasc Ther 2017 Dec 28. Epub 2017 Dec 28.
    Department of nephrology, Affiliated Hospital of Jining Medical College, Jining, China.
    Introduction: Nicorandil has been suggested as a preventative strategy against the incidence of contrast-induced nephropathy (CIN). However, results of relevant randomized controlled trials (RCTs) were inconsistent.

    Aims: We performed a meta-analysis of RCTs to evaluate the preventive efficacy of periprocedural treatment of nicorandil against the incidence of CIN. Read More

    Comparative performance of pharmacogenetics-based warfarin dosing algorithms derived from Caucasian, Asian, and mixed races in Thai population.
    Cardiovasc Ther 2017 Dec 15. Epub 2017 Dec 15.
    Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
    Aim: This study was conducted to compare predictive accuracy of the available pharmacogenetics (PGx)-guided warfarin dosing algorithms derived from Caucasian, Asian, and mixed population to identify a suitable algorithm for Thai population.

    Methods: Ten warfarin dosing algorithms derived from different population including Caucasian, East Asian, South-East Asian, and mixed races were selected and tested with clinical and genetic data of Thai patients. Comparative performances of these algorithms were tested using mean dose error (MDE) between actual warfarin maintenance dose (AWMD) and predicted dose generated by each dosing algorithm, and percentage of ideal dose prediction (IDP). Read More

    Hemodynamic impact of pulmonary vasodilators on single ventricle physiology.
    Cardiovasc Ther 2018 Feb 22;36(1). Epub 2017 Dec 22.
    Pediatric Cardiology Unit, Department of Women's and Children's Health, University of Padua, Padua, Italy.
    Introduction: The Fontan procedure is the palliative procedure for single ventricle physiology. Pulmonary resistance plays a key role in the success of this operation. There are conflicting data concerning the impact of pulmonary vasodilators on survival and functional capacity among Fontan patients. Read More

    The effect of allogeneic cardiac stem cells in left ventricular geometry and function in a rat model of myocardial infarction.
    Cardiovasc Ther 2018 Feb 9;36(1). Epub 2017 Dec 9.
    Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
    Background: The development of heart failure after acute myocardial infarction (MI) was related to left ventricular (LV) pathological remodeling and dysfunction. Cardiac stem cells (CSCs) provided a new option to treat acute MI. This study was to investigate the effects of CSCs on structural and functional alteration in acute MI. Read More

    Tetrahydrobiopterin (BH): Targeting endothelial nitric oxide synthase as a potential therapy for pulmonary hypertension.
    Cardiovasc Ther 2018 Feb 3;36(1). Epub 2017 Dec 3.
    Department of Internal Medicine B, Ziv Medical Center, Safad, Israel.
    Purpose: Pulmonary Hypertension (PH) is complex disease which is associated with endothelial and cardiac dysfunction. Tetrahydrobiopterin (BH) regulates endothelial nitric oxide synthase (eNOS) to produce nitric oxide rather than superoxide which maintains normal endothelial and cardiac function. This study explores the therapeutic potential of BHin experimental PH. Read More

    The APEX trial: Effects of allopurinol on exercise capacity, coronary and peripheral endothelial function, and natriuretic peptides in patients with cardiac syndrome X.
    Cardiovasc Ther 2018 Feb 26;36(1). Epub 2017 Nov 26.
    Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
    The role of endothelial dysfunction and oxidative stress in the pathogenesis of cardiac syndrome X has recently been recognized. Allopurinol has previously been shown to improve endothelial dysfunction, reduce oxidative stress burden, and improve myocardial efficiency. In this "proof of concept" study, we investigated the effect of allopurinol on exercise capacity, coronary and peripheral endothelial function, and serum B-type natriuretic peptide (BNP: a marker of cardiac function and myocardial ischemia) in patients with cardiac syndrome X. Read More

    The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.
    Cardiovasc Ther 2018 Feb 23;36(1). Epub 2017 Nov 23.
    Pfizer Inc., South San Francisco and San Diego, CA, USA.
    Aims: Three single-dose and one multiple-dose phase I studies were conducted in subjects with primary hypercholesterolemia to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of bococizumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

    Methods: The dosing schedules for hypercholesterolemic subjects randomized in the four phase I studies were (1) ascending, single, intravenous (IV) bococizumab (0.3, 1, 3, 6, 12, or 18 mg/kg), or placebo (N = 48; baseline low-density lipoprotein cholesterol [LDL-C] ≥130 mg/dL); (2) single, IV bococizumab (0. Read More

    Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHADSVASc 1 or 2): A treatment dilemma.
    Cardiovasc Ther 2018 Feb 11;36(1). Epub 2017 Nov 11.
    Department of Cardiac, Thoracic and Vascular Sciences, Cardiology Clinic, University of Padua, Padua, Italy.
    Introduction: The issue of anticoagulation in individuals with nonvalvular atrial fibrillation (NVAF) and 1 non-gender-related (NGR) risk factor is subject to debate. The reported risk of stroke in untreated individuals is not uniform, and the rate of hemorrhage associated with anticoagulation in this group of individuals is not well defined. To this end, we assessed the rate of stroke and major hemorrhage in individuals treated with warfarin. Read More

    Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
    Cardiovasc Ther 2018 Feb 25;36(1). Epub 2017 Nov 25.
    Pfizer Inc., South San Francisco and San Diego, CA, USA.
    Aims: Two multiple-dose phase II studies were conducted in subjects with primary hypercholesterolemia to evaluate the LDL-C lowering efficacy, safety, and tolerability of bococizumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

    Methods: The results from the two phase II, double-blinded, randomized, placebo-controlled, multicenter studies conducted in the USA and Canada were combined. In Study 1, 90 subjects with LDL-C ≥100 mg/dL received intravenous (IV) placebo or bococizumab 0. Read More

    Effects of short-term add-on ezetimibe to statin treatment on expression of adipokines and inflammatory markers in diabetic and dyslipidemic patients.
    Cardiovasc Ther 2017 Dec 4;35(6). Epub 2017 Oct 4.
    Department of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
    Aim: The influence of short-term add-on ezetimibe to simvastatin treatment on expression of adipokines and inflammatory markers was investigated in diabetic and nondiabetic patients with hypercholesterolemia.

    Method: Hypercholesterolemic nondiabetic (HC, n = 37) and diabetic (DM, n = 47) patients were treated with simvastatin (SV, 10 or 20 mg/d/8-wk) and then SV plus ezetimibe (SV + EZ, 10 mg each/d/4 wk). Serum lipids, glycemic profile, and inflammatory markers (hsCRP, adiponectin, resistin, VCAM-1, and ICAM-1) were evaluated before and after the add-on ezetimibe therapy. Read More

    Alamandine reverses hyperhomocysteinemia-induced vascular dysfunction via PKA-dependent mechanisms.
    Cardiovasc Ther 2017 Dec 4;35(6). Epub 2017 Oct 4.
    Centre for Chronic Disease, College of Health and Biomedicine, Victoria University, Melbourne, Vic., Australia.
    Introduction: Hyperhomocysteinemia (HHcy) impairs nitric oxide endothelium-dependent vasodilation, consequently leading to atherosclerosis, a risk factor for cardiovascular disease. Novel treatments for HHcy are necessary.

    Aim: We tested the hypothesis that alamandine, a vasoactive peptide of the renin-angiotensin system (RAS), could reverse HHcy-induced vascular dysfunction through the MrgD receptor and that this is mediated by the protein kinase A (PKA) pathway. Read More

    Oxidized low-density lipoprotein (ox-LDL) promotes cardiac differentiation of bone marrow mesenchymal stem cells via activating ERK1/2 signaling.
    Cardiovasc Ther 2017 Dec 27;35(6). Epub 2017 Sep 27.
    Stem Cell and Biotheraphy Technology Research Center, Xinxiang Medical University, Xinxiang, China.
    Background/aims: The differentiation efficiency of bone marrow mesenchymal stem cells (BM-MSCs) is low in vivo after transplantation. Therefore, it is necessary to look for effective reagents for enhancing cardiac differentiation of BM-MSCs. It has been reported that cardiac differentiation of stem cells depends on the activation of extracellular signal-regulated protein 1/2 (ERK1/2) signaling. Read More

    The relationship between knowledge, health literacy, and adherence among patients taking oral anticoagulants for stroke thromboprophylaxis in atrial fibrillation.
    Cardiovasc Ther 2017 Dec 25;35(6). Epub 2017 Sep 25.
    Pharmacy, School of Medicine, University of Tasmania, Hobart, Tas, Australia.
    Background: Patients' knowledge regarding their oral anticoagulant (OAC) treatment for stroke prevention in atrial fibrillation (AF), their level of medication adherence, and health literacy are known to affect treatment outcomes. However, contemporary data regarding the relationships between these variables are lacking.

    Objective: To investigate the relationships between anticoagulant knowledge, health literacy, and self-reported adherence in patients taking warfarin and the directly acting oral anticoagulants. Read More

    Long-term survival following the development of heart failure in an elderly hypertensive population.
    Cardiovasc Ther 2017 Dec 3;35(6). Epub 2017 Oct 3.
    Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic., Australia.
    Background: Available data on the prognosis of heart failure (HF) patients are predominantly limited to patients diagnosed at time of hospitalization.

    Aims: To describe the long-term survival of incident HF patients and identify clinical characteristics associated with mortality.

    Methods: The Second Australian National Blood Pressure Study (ANBP2) randomized 6083 hypertensive subjects aged 65-84 years to angiotensin-converting enzyme (ACE) inhibitor or thiazide diuretic-based therapy and followed them for a median of 4. Read More

    The effect of APOE, CETP, and PCSK9 polymorphisms on simvastatin response in Thai hypercholesterolemic patients.
    Cardiovasc Ther 2017 Dec 25;35(6). Epub 2017 Sep 25.
    School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat, Thailand.
    Aim: To investigate the effect of apolipoprotein E (APOE), cholesteryl ester transfer protein (CETP) and proprotein convertase subtilisin kexin type 9 (PCSK9) polymorphisms on the lipid-lowering response to simvastatin therapy in Thai hypercholesterolemic patients.

    Method: Two hundred and twenty-five hypercholesterolemic patients in southern Thailand were enrolled and treated with simvastatin 20 or 40 mg per day for 3 months. Serum lipids were measured before and after the therapy. Read More

    Cognitive impairment and cardiovascular medication use: Results from wave 1 of The Irish Longitudinal Study on Ageing.
    Cardiovasc Ther 2017 Dec 26;35(6). Epub 2017 Sep 26.
    Division of Population Health Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
    Aim: To explore the association between cardiovascular medication use and cognitive impairment in adults aged 50 years and over.

    Method: This cross-sectional linked database study involved secondary quantitative analysis of 1903 participants from wave 1 of the Irish Longitudinal Study on Ageing with available pharmacy claims data. Cognitive impairment was assessed using a cut-off of ≤23 on the Montreal Cognitive Assessment. Read More

    Iron deficiency in heart failure: Efficacy and safety of intravenous iron therapy.
    Cardiovasc Ther 2017 Dec 25;35(6). Epub 2017 Sep 25.
    Department of Cardiology, Portsmouth Hospitals NHS Trust, Portsmouth, UK.
    Aim: To discuss the pathophysiology of iron metabolism in chronic heart failure (CHF) and the current knowledge of the efficacy of intravenous (IV) iron therapy in patients with CHF and identify points of controversy as well as highlight areas for future research.

    Discussion: Iron deficiency is a recognized complication of many chronic conditions. Numerous studies have reported that iron deficiency is highly prevalent in patients with CHF and is associated with exercise intolerance, reduced quality of life, and increased risk of hospitalization and mortality. Read More

    The vasorelaxant effect of antidiabetic drug nateglinide via activation of voltage-dependent Kchannels in aortic smooth muscle.
    Cardiovasc Ther 2018 Feb 25;36(1). Epub 2017 Oct 25.
    Department of Physiology, Kangwon National University School of Medicine, Chuncheon, South Korea.
    Aims: We investigated the vasorelaxant effect of nateglinide and its related mechanisms using phenylephrine (Phe)-induced precontracted aortic rings.

    Methods: Arterial tone measurement was performed in aortic smooth muscle.

    Results: The application of nateglinide induced vasorelaxation in a concentration-dependent manner. Read More

    Comparison of anticoagulation regimens for pregnant women with prosthetic heart valves: A meta-analysis of prospective studies.
    Cardiovasc Ther 2017 Dec;35(6)
    Qindao University Medical College Affiliated Yantai Yuhuangding Hospital, Yantai, Shandong, China.
    Introduction: Pregnancy is associated with a hypercoagulable state, which makes pregnant women with prosthetic heart valves at high risk of thromboembolism. The proper anticoagulation regimen should take both the maternal protection and the fetal outcomes into consideration. However, no consensus on the present anticoagulation regimen for those women has been reached yet, especially in the first trimester of pregnancy. Read More

    Predictors of candesartan's effect on vascular reactivity in patients with coronary artery disease.
    Cardiovasc Ther 2017 Oct;35(5)
    Division of Cardiology, Department of Internal Medicine/Cardiovascular Center, Seoul National University Hospital, Seoul, Korea.
    Introduction And Aims: Endothelial dysfunction and arterial stiffness have a prognostic value on adverse long-term outcomes in coronary artery disease (CAD) patients. We evaluated the efficacy on vascular reactivity of candesartan and analyzed predictors to control the candesartan's effect on vascular reactivity in CAD patients.

    Method: Patients were prospectively enrolled and prescribed candesartan for 6 months. Read More

    Microcatheter balloon pinning technique to facilitate wiring of a left circumflex chronic total occlusion.
    Cardiovasc Ther 2017 Dec;35(6)
    Division of Cardiology, Department of Internal Medicine, Baylor Heart and Vascular Institute, Baylor University Medical Center at Dallas, Dallas, TX, USA.
    Introduction: Coronary chronic total occlusions (CTOs) are commonly encountered during diagnostic angiograms. With recent advances, especially in experienced centers, success rates with CTO percutaneous coronary intervention (PCI) have approached 80% or higher. It is important to note that despite these advancements in techniques, CTOs remain difficult to treat. Read More

    High-dose Humanin analogue applied during ischemia exerts cardioprotection against ischemia/reperfusion injury by reducing mitochondrial dysfunction.
    Cardiovasc Ther 2017 Oct;35(5)
    Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
    Aim: Although the gold standard treatment for acute myocardial infarction is reperfusion therapy, reperfusion itself can cause myocardial damage via induction of cardiac mitochondrial dysfunction. This can lead to increased myocardial infarct size, arrhythmias, and left ventricular (LV) dysfunction. Recently, a newly discovered peptide, Humanin, has been shown to exert several beneficial effects including antioxidative and antiapoptosis effects. Read More

    Cholinesterase inhibition reduces arrhythmias in asymptomatic Chagas disease.
    Cardiovasc Ther 2017 Oct;35(5)
    Department of Physiology and Pharmacology and Post-Graduate Program in Cardiovascular Sciences, Fluminense Federal University, Niterói, Brazil.
    Introduction: Parasympathetic dysfunction may play a role in the genesis of arrhythmias in Chagas disease.

    Aim: This study evaluates the acute effects of pyridostigmine (PYR), a reversible cholinesterase inhibitor, on the occurrence of arrhythmias in patients with Chagas cardiac disease.

    Method: Following a double-blind, randomized, placebo-controlled, cross-over protocol, 17 patients (age 50±2 years) with Chagas cardiac disease type B underwent 24-hour Holter recordings after oral administration of either pyridostigmine bromide (45 mg, 3 times/day) or placebo (PLA). Read More

    Inhibition of mevalonate pathway prevents ischemia-induced cardiac dysfunction in rats via RhoA-independent signaling pathway.
    Cardiovasc Ther 2017 Oct;35(5)
    Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
    Aim: We previously demonstrated that anoxia-mediated Cahandling dysfunction could be ameliorated through inhibition of mevalonate pathway via RhoA- and Ras-related mechanisms in H9c2 cells. In this study, we further explored whether inhibition of mevalonate pathway is associated with cardiac remodeling and dysfunction in ischemic cardiomyopathy, and discussed the possible role of Ras, Rac and RhoA in cardiac dysfunction.

    Methods: We investigated the role of mevalonate pathway in cardiac remodeling and cardiomyocyte Cahandling proteins expression in a rat model of cardiac dysfunction due to myocardial infarction (MI). Read More

    Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits.
    Cardiovasc Ther 2017 Oct;35(5)
    Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.
    Background/aims: Recent evidence indicates that peroxisome proliferator-activated receptor (PPAR)-γ activators exert anti-inflammatory and antioxidant actions. However, the underlying mechanisms by which these agents prevent atrial remodeling in diabetes are not completely elucidated. We sought to investigate the potential effects of pioglitazone, a PPAR-γ activator, on atrial remodeling and atrial fibrillation (AF) inducibility in diabetic rabbits. Read More

    MiR-195 promotes abdominal aortic aneurysm media remodeling by targeting Smad3.
    Cardiovasc Ther 2017 Dec;35(6)
    Department of Cardiothoracic Surgery, Huaihe Hospital of Henan University, Kaifeng, China.
    Introduction: MiR-195 has been implicated in the development of abdominal aortic aneurysms (AAA). However, the underlying mechanisms have not been fully addressed.

    Aim: To explore the roles of miR-195 in regulating the proliferation and apoptosis of vascular smooth muscle cells (VSMCs), as well as its molecular basis in vitro. Read More

    Comparative evaluation of torasemide and spironolactone on adverse cardiac remodeling in a rat model of dilated cardiomyopathy.
    Cardiovasc Ther 2017 Oct;35(5)
    Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan.
    Background: Chronic heart failure (CHF) involves fluid retention and volume overload, leading to impaired cardiac function. In these conditions, diuretic agents are most commonly used to treat edema and thereby reducing the volume load on the failing heart. There are several other beneficial effects of diuretics apart from their action on urinary excretion. Read More

    Pitavastatin up-regulates eNOS production by suppressing miR-155 expression in lipopolysaccharide-stimulated human umbilical vein endothelial cells.
    Cardiovasc Ther 2017 Oct;35(5)
    Department of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, Henan, China.
    Aim: Pitavastatin (Pit) has been proved to efficiently inhibit the onset and progression of atherosclerosis. However, the mechanism by which Pit exerts nonlipid-related effects, such as antiinflammatory actions, is not quite clear. Our study aimed at investigating the effect of Pit on the expression of endothelial NO synthase (eNOS) and miR-155 in LPS-stimulated HUVECs to reveal the antiinflammatory mechanism of pitavastatin. Read More

    Critical role of TNF inhibition in combination therapy for elderly mice with atherosclerosis.
    Cardiovasc Ther 2017 Dec;35(6)
    Department of Pharmacy, Integrated Research Institute of Pharmaceutical Sciences, and BK21 PLUS Team for Creative Leader Program for Pharmacomics-based Future Pharmacy, College of Pharmacy, The Catholic University of Korea, Bucheon-si, Gyeonggi-do, Korea.
    Aims: We have previously shown that the combination of pravastatin and sarpogrelate is synergistically beneficial for atherosclerosis. In this study, we investigated whether the pravastatin-sarpogrelate combination was sufficient for treatment in an old mouse model of atherosclerosis or if additional intervention would be needed to address the newly included aging factor and its complex pathophysiological impact on the atherosclerogenic state. We added an anti-TNF biological to the combination treatment cocktail because of the known pathologic roles of TNF in the aging process. Read More

    Postconditioning with metformin attenuates apoptotic events in cardiomyoblasts associated with ischemic reperfusion injury.
    Cardiovasc Ther 2017 Dec 20;35(6). Epub 2017 Oct 20.
    Department of Biochemistry, Kerala University, Thiruvananthapuram, Kerala, India.
    Aim: Ischemic postconditioning is considered as a potent method to combat ischemic reperfusion injury than preconditioning and rapid initiation of reperfusion with potent antioxidant compounds can be one of the most effective treatments to reduce the infarct size and behavioral deficits as a result of ischemic insult. The present study aims to determine the postconditioning effects of metformin in experimental ischemia.

    Methods: H9C2 cells were subjected to experimental ischemia and reperfused with metformin. Read More

    Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil.
    Cardiovasc Ther 2017 Oct;35(5)
    Department of Pulmonary, Allergy and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA.
    Introduction: Anticoagulation is a common treatment modality in patients with pulmonary arterial hypertension (PAH). Further studies are needed to appropriately assess the risk/benefit ratio of anticoagulation, particularly in PAH patients receiving PAH-specific therapies.

    Aims: We use observational long-term data on PAH patients treated with subcutaneous (SQ) treprostinil from a large open-label study. Read More

    Sulforaphane protection against the development of doxorubicin-induced chronic heart failure is associated with Nrf2 Upregulation.
    Cardiovasc Ther 2017 Oct;35(5)
    The Jilin Province People's Hospital, Changchun, China.
    Background: Doxorubicin (DOX) is an anthracycline antitumor drug. However, its clinical use is limited by dose-dependent cardiotoxicity and even progresses to chronic heart failure (CHF).

    Objective: This study aims to investigate whether the Nrf2 activator, sulforaphane (SFN), can prevent DOX-induced CHF. Read More

    Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301].
    Cardiovasc Ther 2017 Oct;35(5)
    Global Product Development CVMET Therapeutics, Pfizer Inc, New York, NY, USA.
    Aim: To characterize the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of bococizumab, a monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), administered subcutaneously (s.c.) to the abdomen, thigh, or upper arm (NCT02043301). Read More

    Exploring the putative role of TRPV-dependent CGRP release in remote hind preconditioning-induced cardioprotection.
    Cardiovasc Ther 2017 Oct;35(5)
    Department of Pharmaceutical Sciences and Drug Research, Punjabi University Patiala, Patiala, India.
    Background: Remote ischemic preconditioning (RIPC) is a phenomenon whereby transient nonlethal ischemia and reperfusion episodes confer protection against prolonged ischemia reperfusion-induced injury. However, the underlying intracellular signaling has not been extensively explored.

    Objective: This study aimed to inspect the putative involvement of TRPV-dependent CGRP release in mediating remote hind limb preconditioning-induced cardioprotection. Read More

    Effects of conjugated linoleic acid supplementation on serum C-reactive protein: A systematic review and meta-analysis of randomized controlled trials.
    Cardiovasc Ther 2017 Dec;35(6)
    Division of Medical Education, Brighton and Sussex Medical School, Falmer, Brighton, UK.
    Aim: To undertake a systematic review and meta-analysis of prospective studies to determine the effect of conjugated linoleic acids (CLAs) supplementation on serum C-reactive protein (CRP).

    Method: PubMed-Medline, Web of Science, Cochrane Database, and Google Scholar databases were searched (up until May 2016) to identify prospective studies evaluating the impact of CLAs supplementation on serum CRP. Random-effects models meta-analysis was used for quantitative data synthesis. Read More

    Visit-to-visit systolic blood pressure variability predicts treatment-related adverse event of hyponatremia in SPRINT.
    Cardiovasc Ther 2017 Aug;35(4)
    Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA.
    Hypertension is a common condition and an important cardiovascular risk factor. SPRINT trial showed that the beneficial effects of targeting systolic blood pressure <120 mm Hg were accompanied by more adverse events. De-identified SPRINT database was used for this analysis. Read More

    Endothelial damage effects of circulating microparticles from patients with stable angina are reduced by aspirin through ERK/p38 MAPKs pathways.
    Cardiovasc Ther 2017 Aug;35(4)
    Department of Cardiology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China.
    Introduction: Platelet activation participates in the development of both coronary artery disease (CAD) and circulating microparticles (MPs). As a commonly used medicine for coronary heart disease, whether aspirin affects the function of MPs remains unclear.

    Aims: This study was designed to test MPs from healthy subjects, and stable angina (SA) patients before and after aspirin administration were obtained. Read More

    Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects.
    Cardiovasc Ther 2017 Aug;35(4)
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.
    The development of the promising agent sacubitril/valsartan, known as an angiotensin receptor blocker-neprilysin inhibitor (ARNI), to improve heart failure (HF) management, may benefit morbidity, mortality, and readmission rates in patients with HF. The PARADIGM-HF trial demonstrated that the ARNI can reduce morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF), while ongoing PARAMOUNT and PARAGON-HF trials determined whether the ARNI has morbidity and mortality benefits in patients with heart failure with preserved ejection fraction (HFpEF). However, the risk of long-term side effects of the ARNI such as cognitive dysfunction or Alzheimer's disease (AD) remains unknown. Read More

    Association of body mass index with mortality in Chinese patients after percutaneous coronary intervention: A large single-center data.
    Cardiovasc Ther 2017 Aug;35(4)
    Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China.
    Background: Although numerous studies, to date, have demonstrated a specific phenomenon called the "obesity paradox" in patients after percutaneous coronary intervention (PCI), studies performed in China thus far have consistently shown an absence of this phenomenon.

    Hypothesis: "Obesity paradox" does exist in Chinese PCI patients.

    Methods: 10 724 consecutive Chinese patients who had undergone PCI treatment at a single center from January 2013 to December 2013 were prospectively recruited. Read More

    Gender-related differences in antiplatelet treatment patterns and outcome: Insights from the GReekAntiPlatElet Registry.
    Cardiovasc Ther 2017 Aug;35(4)
    Department of Cardiology, Patras University Hospital, Patras, Greece.
    Aims: Data on the clinical impact of gender in "real-life" patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), receiving clopidogrel, prasugrel, or ticagrelor are limited. We aimed to investigate sex-based differences in clinical outcome of those patients.

    Methods: In a prospective, observational, multicenter, cohort study, 2047 patients were recruited into the GReekAntiPlatElet (GRAPE) Registry and were followed up until 1 year for major adverse cardiovascular events (MACE, composite of death, nonfatal myocardial infarction, urgent revascularization, and stroke) and bleeding events (Bleeding Academic Research Consortium [BARC] classification). Read More

    1 OF 12